A drug called Dostarlimab has left many doctors in shock after proving to be 100% effective in treating colorectal cancer. The welcome discovery was made during human clinical trials, and many scientists worldwide couldn't be happier.

Not surprisingly, many people already think the drug represents the future of cancer treatment.

Dostarlimab was made using lab-produced molecules that behave like substitute antibodies once introduced into the body. All the 18 subjects involved in the study were in remission after just a year of treatment using the new miracle drug.

After the discovery that the drug was working better than expected, doctors started to do endoscopies, PET scans, MRIs, and physical tests to see if the patients had any cancer left in their bodies.

However, they were pleasantly surprised to find no cancer in the subjects.

According to Dr. Luis A. DIaz Jr., who works at the Memorial Sloan Kettering Cancer Center, this has never happened before in the history of cancer research.

Dr. Diaz and his fellow researchers published a paper in the New England Journal of Medicine based on their findings. The article details their incredible results.

The shocking discovery has caused quite a buzz in the medical world.

According to Dr. Alan P. Venook, a colorectal cancer specialist at the University of California, it is "unheard of" for complete remission to be witnessed in every patient during such studies. Although Venook was not part of the team researching the drug, he pointed out that such results have never been achieved.

Dr. Venook also took note that even though the results obtained were impressive, there were no serious side effects as far as the drug was concerned.

The 18 patients involved in the study were previously exposed to other burdensome treatments. Some of these interventions included chemotherapy, radiation, and invasive surgery that would have likely resulted in the bowel, urinary, and sexual dysfunction.

When the patients got into the trial, they expected to experience severe side effects after taking the treatment. However, that never happened.

They did not need further treatment once the trial was over.

Memorial Sloan Kettering Cancer Center and Dr. Andrea Cercek, one of the paper's co-authors, talked about the time the patients found out they no longer had cancer.

In general, "there were a lot of happy tears."

Cancer Australia has revealed that colorectal cancer, also called bowel cancer, affects 100,000 Australians yearly.

In other words, the impact the new drug has had in the world of medicine is being felt in a lot of places.

In May of this year, a group of doctors in the United States revealed new groundbreaking research. They had injected a human patient (for the first time) with a genetically modified virus that could kill cancer.

The media said that the drug, called Vaxinia, has already been successful in animal tests. Therefore, medical professionals and researchers are hopeful that the same results will be observed in humans.

Already, the virus has been seen to shrink colon, lung, breast, ovarian, and pancreatic cancer tumors during animal trials.